Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Boehringer Ingelheim

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Evogliptin

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Evogliptin: Sponsors, patents, clinical trial progress

Evogliptin is an investigational drug.

There have been 14 clinical trials for Evogliptin. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2016.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Liver Diseases. The leading clinical trial sponsors are Dong-A ST Co., Ltd., Samsung Medical Center, and Eurofarma Laboratorios S.A.

There are five US patents protecting this investigational drug and ninety-six international patents.

Recent Clinical Trials for Evogliptin
Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver DiseasesDong-A ST Co., Ltd.Phase 4
Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male AdultsDong-A ST Co., Ltd.Phase 1
Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal InsufficiencySamsung Medical CenterPhase 2

See all Evogliptin clinical trials

Clinical Trial Summary for Evogliptin

Top disease conditions for Evogliptin
Top clinical trial sponsors for Evogliptin

See all Evogliptin clinical trials

US Patents for Evogliptin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Evogliptin   Start Trial Composition containing a DPP-IV inhibitor for preventing or treating renal diseases DONG-A ST Co., Ltd (Seoul, KR)   Start Trial
Evogliptin   Start Trial DPP-IV inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating diabetes or obesity Dong-A Pharm. Co., Ltd. (Seoul, KR)   Start Trial
Evogliptin   Start Trial Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-IV, and other antidiabetic or antiobesity agents as active ingredients Dong-A Pharmaceutical Co. Ltd. (Seoul, KR)   Start Trial
Evogliptin   Start Trial Method for manufacturing dipeptidyl peptidase-IV inhibitor and intermediate Dong-A Pharmaceutical. Co., Ltd (Seoul, KR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Evogliptin

Drugname Country Document Number Estimated Expiration Related US Patent
Evogliptin Australia 2014299575 2033-06-26   Start Trial
Evogliptin Brazil 112015032410 2033-06-26   Start Trial
Evogliptin Canada 2916698 2033-06-26   Start Trial
Evogliptin China 105555275 2033-06-26   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.